In this preprint, Gao et al. describe the first evidence of vaccine efficacy against COVID-19 in non-human primates. A patient-derived SARS-CoV-2 isolate was expanded then inactivated with β-propiolactone. Rhesus macaques were immunized three times with inactivated virus plus alum, then challenged 1 week later with a virus from a different isolate. Although SARS-CoV-2 infection of rhesus macaques doesn’t fully recapitulate human pathophysiology, vaccinated macaques had no symptoms and a rapid decrease in viral loads. Vaccine safety was assessed in additional macaques that showed no immediate adverse effects. This inactivation technique is well known and adaptable for production in other facilities, which argues for scalability. Phase I and II clinical trials are underway.
References
Original article
Gao, Q. et al. Rapid development of an inactivated vaccine for SARS-CoV-2. Preprint at bioRxiv https://doi.org/10.1101/2020.04.17.046375 (2020)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Risson, E. Inactivated vaccine for SARS-CoV-2. Nat Rev Immunol 20, 353 (2020). https://doi.org/10.1038/s41577-020-0334-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41577-020-0334-1
This article is cited by
-
Adaptive immune responses and cytokine immune profiles in humans following prime and boost vaccination with the SARS-CoV-2 CoronaVac vaccine
Virology Journal (2022)
-
Current vaccine technology with an emphasis on recombinant measles virus as a new perspective for vaccination against SARS-CoV-2
Euro-Mediterranean Journal for Environmental Integration (2021)